AB logo

AB Science S.A. Stock Price

ENXTPA:AB Community·€92.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

AB Share Price Performance

€1.26
0.30 (30.64%)
€1.26
0.30 (30.64%)
Price €1.26

AB Community Narratives

There are no narratives available yet.

Snowflake Analysis

Moderate risk with imperfect balance sheet.

5 Risks
1 Reward

AB Science S.A. Key Details

€1.0m

Revenue

€95.0k

Cost of Revenue

€932.0k

Gross Profit

€9.5m

Other Expenses

-€8.5m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.12
90.75%
-831.45%
-66.6%
View Full Analysis

About AB

Founded
2001
Employees
36
CEO
Alain Moussy
WebsiteView website
www.ab-science.com

AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company’s lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer’s disease, and indolent systemic mastocytosis, as well as in Phase 2 trial for mast cell activation syndrome and sickle cell disease. It also develops AB8939, a microtubule destabilizer in Phase 1 trial for the treatment of acute myeloid leukemia; and AB12319 in preclinical trial to treat sarcoma and solid tumors. In addition, the company markets its masitinib under the Masivet brand for the treatment of mast cell tumors in dogs in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

Recent AB News & Updates

Recent updates

No updates